Keizer, B. de

patient carcinoid lu-octreotate crisis therapy 177 lu-octreotate tumor somatostatin 177 lu-octreotate therapy analogue 177 luoctreotate treatment octreotide metastatic carcinoid crisis metastase cycle luoctreotate pheochromocytoma liver somatostatin analogues diarrhea neuroendocrine neuroendocrine tumors metastatic pheochromocytoma flushing release somatostatin analogue therapy liver metastases /24 crises administration receptor vipoma syndrome herder ww carcinoid syndrome imaging side effects radionuclide normetanephrine discontinuation hospitalization herder corticosteroids fluid peptide 479 patients disease tract carcinoid octreotide treatment therapy cycle 177 lu-octreotate infusion bone metastases symptom 177 luoctreotate treatment 177 lu-octreotate treatment receptor radionuclide therapy continuation 24- h urine 1 year tumor lysis nausea kooij pp gepnet gastrin radiolabeled characteristic infusion table effect symptomatology january uptake patient 6 tract beta irradiation carcinoid tumours cga flushing hypotension